- Home
- APRE vs SNSE Comparison
APRE vs SNSE Comparison
Compare APRE & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- SNSE
- Stock Information
- Founded
- APRE 2006
- SNSE 2005
- Country
- APRE United States
- SNSE United States
- Employees
- APRE N/A
- SNSE N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- SNSE Health Care
- Exchange
- APRE Nasdaq
- SNSE Nasdaq
- Market Cap
- APRE 9.7M
- SNSE 9.3M
- IPO Year
- APRE 2019
- SNSE 2021
- Fundamental
- Price
- APRE $1.75
- SNSE $0.34
- Analyst Decision
- APRE Strong Buy
- SNSE Strong Buy
- Analyst Count
- APRE 2
- SNSE 4
- Target Price
- APRE $15.50
- SNSE $4.25
- AVG Volume (30 Days)
- APRE 35.9K
- SNSE 150.7K
- Earning Date
- APRE 05-14-2025
- SNSE 05-06-2025
- Dividend Yield
- APRE N/A
- SNSE N/A
- EPS Growth
- APRE N/A
- SNSE N/A
- EPS
- APRE N/A
- SNSE N/A
- Revenue
- APRE $1,284,475.00
- SNSE N/A
- Revenue This Year
- APRE N/A
- SNSE N/A
- Revenue Next Year
- APRE N/A
- SNSE N/A
- P/E Ratio
- APRE N/A
- SNSE N/A
- Revenue Growth
- APRE 33.27
- SNSE N/A
- 52 Week Low
- APRE $1.41
- SNSE $0.25
- 52 Week High
- APRE $5.01
- SNSE $0.87
- Technical
- Relative Strength Index (RSI)
- APRE 49.51
- SNSE 50.22
- Support Level
- APRE $1.60
- SNSE $0.31
- Resistance Level
- APRE $2.00
- SNSE $0.33
- Average True Range (ATR)
- APRE 0.16
- SNSE 0.04
- MACD
- APRE 0.02
- SNSE 0.01
- Stochastic Oscillator
- APRE 37.50
- SNSE 75.25
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).